Medication for Body Dysmorphic Disorder: The Clinical Answer
Medication for body dysmorphic disorder (BDD) is centered on serotonin reuptake inhibitors, especially selective serotonin reuptake inhibitors (SSRIs), prescribed and monitored by a qualified clinician. Fluoxetine has the strongest direct placebo-controlled SSRI evidence for BDD and is specifically recommended as the initial pharmacological treatment in the UK NICE guideline. Other SSRIs, including escitalopram, sertraline, and fluvoxamine, may be selected according to prior response, coexisting conditions, interactions, tolerability, and local prescribing rules. Clomipramine, a tricyclic antidepressant with powerful serotonin reuptake inhibition, is a specialist alternative after an insufficient or poorly tolerated SSRI trial. Cognitive behavioral therapy (CBT) adapted for BDD remains an evidence-based treatment, and combined CBT and an SSRI is recommended when impairment is severe. NICE CG31; Rück et al., 2024.
BDD medication decisions address a clinical syndrome characterized by persistent preoccupation with perceived appearance defects that other people do not observe or see as slight, accompanied by repetitive behaviors or mental acts and significant distress or functional impairment. Medication is not indicated solely because someone dislikes a feature of their appearance. The clinician first evaluates diagnostic criteria, the degree of impairment, previous treatment, suicidality, medical history, and whether another condition more accurately explains the problem. Rück et al., 2024.
The evidence warrants precise language. There is controlled efficacy evidence for fluoxetine and clomipramine, a randomized continuation study of escitalopram among responders, observational evidence for several other SSRIs, and specialist consensus about sequencing and adjunctive treatment. Robust comparative trials that identify a universally best SSRI or establish the optimal individual dose are missing. Medication choices therefore require individualized shared clinical decisions rather than a universal drug list or a self-directed dosage schedule. Castle et al., 2021; Rück et al., 2024.
What Medication Is Treating in BDD
Preoccupation, rituals, avoidance, and impairment
The core target is the disorder's cycle of distressing appearance-focused thoughts, compulsive checking or grooming, requests for reassurance, camouflage, comparison, avoidance, and disrupted functioning. A person may spend hours scrutinizing skin, hair, body shape, or facial features; cancel social engagements; avoid photographs; or repeatedly seek cosmetic changes. Treatment response is measured through changes in the intensity of preoccupation, repetitive behaviors, distress, insight, avoidance, and everyday functioning, rather than an alteration in physical appearance. Rück et al., 2024.
BDD often co-occurs with major depression, social anxiety disorder, obsessive-compulsive disorder (OCD), or substance use. Clinicians must establish which symptoms belong to BDD and which require parallel care. For example, a person with an eating disorder may have weight- or shape-related concerns embedded in eating pathology, while muscle dysmorphia is a BDD specifier with its own muscularity-centered presentation. Co-occurrence can change assessment, urgency, medication suitability, and the goals of psychotherapy. Castle et al., 2021; Rück et al., 2024.
Why serotonin reuptake inhibitors are used
SSRIs inhibit the serotonin transporter and increase extracellular serotonin signaling. They are established treatments for several psychiatric disorders, including depression and OCD. Their efficacy in BDD has been demonstrated clinically, although the response does not establish a simple serotonin-deficiency theory of BDD. The disorder involves interacting perceptual, emotional, cognitive, behavioral, and social processes. Medication can reduce symptom severity and help people participate in psychological treatment, while the precise mechanisms that explain BDD response remain incompletely understood. Castle et al., 2021; Rück et al., 2024.
The term serotonin reuptake inhibitor (SRI) is broader than SSRI. It includes clomipramine, which is a tricyclic antidepressant, while SSRI denotes agents such as fluoxetine and sertraline. This distinction matters because clomipramine has a different side-effect and monitoring profile. An evidence-based review must therefore distinguish SSRI data from the broader class of serotonin-reuptake treatments. Hollander et al., 1999.
Which SSRIs Have Evidence for Body Dysmorphic Disorder?
Fluoxetine: the strongest direct placebo-controlled SSRI trial
In a 12-week randomized, double-blind study, 67 participants with BDD were randomized to fluoxetine or placebo. A clinically meaningful reduction in BDD symptoms occurred in 53% of the fluoxetine group compared with 18% of the placebo group. The groups began to separate significantly around week eight, a finding relevant to how treatment progress is reviewed. This was a relatively small trial, and its results should not be represented as a guaranteed probability of benefit for any particular patient. Phillips, Albertini, and Rasmussen, 2002.
NICE CG31 recommends fluoxetine when medication is initiated for adults with BDD, including patients whose appearance beliefs have delusional intensity, because its direct BDD evidence was strongest in the guideline review. NICE also specifies that this use is off-label in its jurisdiction. An off-label prescription means the regulatory product authorization does not explicitly list that indication; it does not mean the treatment lacks research support. Regulatory approval varies by country and formulation and must be checked by the prescribing clinician. NICE CG31.
Escitalopram: acute response and relapse-prevention evidence
An important escitalopram study first treated 100 adults with BDD openly for 14 weeks. Among all enrolled participants, 67% met the study's response definition. Fifty-eight responders then entered the randomized six-month continuation phase, receiving escitalopram or a switch to placebo. Relapse occurred in 18% of those maintained on escitalopram compared with 40% of those switched to placebo, and the time to relapse was longer with continued treatment. More than one-third of escitalopram continuers experienced further improvement. Phillips et al., 2016.
This design supports continuation among people who have already responded to escitalopram. Its initial phase was open-label, so the 67% acute response rate is not a placebo-adjusted efficacy estimate. Only responders entered the randomized discontinuation experiment. Findings should therefore inform maintenance discussions without being generalized as proof that escitalopram is superior to other SSRIs or will help two-thirds of all people starting treatment in ordinary care. Phillips et al., 2016.
Sertraline, fluvoxamine, citalopram, and other SSRIs
Clinicians sometimes use sertraline, fluvoxamine, and other SSRIs for BDD, drawing on smaller open-label studies, clinical experience, response to related conditions, and the wider evidence base for obsessive-compulsive-spectrum care. Uncontrolled improvement cannot fully separate medication effects from expectancy, regression toward the mean, concomitant care, or the disorder's natural variation. There are no large head-to-head trials establishing a stable efficacy ranking among SSRIs specifically for BDD. Castle et al., 2021; Phillips, 2010.
Drug selection is also a matter of safety. Some SSRIs have substantial drug–drug interaction potential; some may be more likely to cause discontinuation symptoms after abrupt interruption; and citalopram carries dose-related QT-prolongation concerns. A prior successful or unsuccessful treatment, concurrent medications, cardiac history, other diagnoses, pregnancy plans, and patient preferences all affect an informed decision. Prescribers use current product labeling and clinical resources rather than extrapolating a dose from another person's experience. NICE CG31; Castle et al., 2021.
Clomipramine and the Evidence Beyond SSRIs
Why clomipramine is different
Clomipramine is a tricyclic antidepressant with strong serotonin reuptake inhibition. In a 16-week double-blind crossover trial, clomipramine reduced BDD symptoms and functional impairment more effectively than desipramine, a predominantly noradrenergic tricyclic. The trial enrolled 40 patients, with 29 randomized to the crossover comparison. It supplied important early controlled support for the relevance of serotonin reuptake treatment, but its modest size limits conclusions about comparative effectiveness in contemporary practice. Hollander et al., 1999.
Clomipramine generally demands closer consideration of anticholinergic effects, sedation, orthostatic symptoms, cardiac conduction or rhythm risk, seizure threshold, overdose toxicity, and interactions. Depending on individual risk factors, clinicians may require a physical examination, ECG, medication reconciliation, or additional monitoring. NICE places clomipramine after an inadequate or poorly tolerated SSRI trial, or where earlier good response and patient preference make it appropriate. Combining serotonergic medications without specialist oversight can produce serious toxicity. NICE CG31; Hollander et al., 1999.
Antipsychotic augmentation and other proposed medications
Antipsychotics are sometimes discussed when BDD remains disabling despite established treatment or when another diagnosis independently calls for them. The evidence for routine antipsychotic augmentation in BDD is limited and far weaker than the evidence for SSRIs. Evidence from OCD cannot simply be transferred to BDD. Likewise, isolated case reports or small uncontrolled experiences with other adjunctive agents do not establish general effectiveness, optimal sequencing, or safety in people with BDD. The 2021 international consensus discusses potential adjuncts as specialist options while emphasizing the lack of large BDD trials. Castle et al., 2021.
Crucially, firm conviction that an appearance defect is real does not automatically imply schizophrenia or make antipsychotic medication the first treatment for BDD. Delusional intensity can be specified within BDD itself; controlled studies found that serotonin reuptake treatments can benefit people with poor insight or delusional-level conviction. Clinicians still investigate hallucinations, disorganization, mood episodes, and other symptoms when a separate psychotic or mood disorder is possible. Hollander et al., 1999; NICE CG31.
Medications used for insomnia, anxiety, or depression may sometimes treat a comorbid symptom or separate condition. They should not be presented as proven standalone BDD treatments without BDD-specific efficacy evidence. NICE advises against routinely using most other tricyclic antidepressants, serotonin–norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, or anxiolytics to treat uncomplicated BDD, apart from narrowly defined situations such as short-term management of early SSRI activation. NICE CG31.
How Medication Fits Into a Treatment Plan
Mild, moderate, and severe impairment
The level of impairment guides initial choices. NICE recommends BDD-focused CBT with exposure and response prevention (ERP) for adults whose impairment is mild. With moderate impairment, it recommends a choice between an SSRI and more intensive individual CBT adapted for BDD. With severe impairment, it recommends combined SSRI and BDD-focused CBT. These are recommendations from a UK guideline, not a substitute for considering local clinical standards, accessibility, coexisting conditions, and the person's informed preferences. NICE CG31.
A person may prefer psychotherapy, medication, or both. Effective shared decision-making explores expected benefits, adverse effects, previous treatment, the burden of appearance rituals, safety needs, and the feasibility of attending sessions. BDD-specific CBT addresses distorted interpretations of appearance, avoidance, repeated checking, reassurance seeking, and feared social situations. Medication may reduce distress and compulsive symptoms enough to facilitate these behavioral changes, while therapy builds learning and skills that a prescription alone does not explicitly teach. Jonathan et al., 2024; Rück et al., 2024.
Assessment before a prescription
A comprehensive evaluation establishes the nature of the appearance preoccupation, time occupied, repetitive behaviors, avoidance, impairment, and insight. It considers an eating-disorder presentation, muscle dysmorphia, social anxiety, OCD, major depressive disorder, and related conditions. A clinician also asks about earlier medication trials, adherence, substance use, medical illnesses, current prescriptions and supplements, bipolar-spectrum symptoms, and personal or family history relevant to antidepressant risks. Medication decisions follow assessment; a screening questionnaire alone cannot authorize or determine pharmacotherapy. Castle et al., 2021; Rück et al., 2024.
Severity can be tracked using the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS), alongside ratings of insight, depressive symptoms, quality of life, school or workplace participation, and day-to-day avoidance. A clinician may also review time spent on appearance concerns, repeated cosmetic consultations, and distress around photographs or social situations. Change in a scale score helps monitor progress but must be interpreted alongside functioning and safety. The response definitions used in trials are research thresholds rather than universal rules for an individual's recovery. Phillips et al., 2002; Phillips et al., 2016.
Starting, adjusting, and reviewing an SSRI
The prescriber ordinarily begins with an individually appropriate regimen, reviews tolerability and clinical changes, and adjusts treatment progressively. Because BDD response may develop slowly, a few symptom-heavy early weeks do not by themselves establish failure. NICE advises checking adherence and interactions, and considering a gradual increase after four to six weeks without adequate response to a standard dose if significant adverse effects are absent. It calls for monitoring during increases and around any symptom worsening. NICE CG31.
BDD studies and specialist reviews describe treatment trials extending around 12 to 16 weeks; the exact adequacy of a trial depends on duration, tolerated exposure, adherence, response, and safety. Some specialist literature notes that people with BDD may require higher doses than those usually used for depression, but no controlled BDD dose-finding trial establishes one optimal target. An above-label dose is a specialist risk–benefit decision, never an instruction for self-escalation. Regulatory maximums, QT risk, interactions, age, and the prescribing jurisdiction matter. Rück et al., 2024; Castle et al., 2021.
A useful review documents symptoms and functioning at baseline, revisits treatment goals, identifies adverse effects and adherence problems, and evaluates whether CBT is available and effective. Small changes can be meaningful when they restore school attendance, interpersonal contact, or the ability to leave home without prolonged rituals. At the same time, treatment should be revised promptly when there are intolerable adverse reactions, new mania, dangerous agitation, or escalating suicide risk. NICE CG31.
Adverse Effects, Interactions, and Medication Safety
Common effects and what clinicians monitor
Potential SSRI adverse effects include nausea, gastrointestinal symptoms, headache, sleep disturbance, increased or reduced sleepiness, sweating, tremor, initial anxiety or agitation, and sexual dysfunction. Some effects fade as the body adapts, while others persist and require discussion of the medication or dose. Weight change and emotional blunting may be relevant for some people. Adverse effects matter particularly in BDD because new appearance or bodily concerns may intensify existing preoccupation; patient-centered follow-up should take both physical experiences and psychological responses seriously. Phillips et al., 2016; NICE CG31.
Prescribers should review potential serotonin syndrome when multiple serotonergic drugs or certain interacting medications are used; bleeding risks when an SSRI is combined with antiplatelet agents, anticoagulants, or some analgesics; cardiac risk with QT-prolonging drugs; and the possibility of hyponatremia in susceptible people. Important interactions can occur with over-the-counter products and herbal supplements as well as prescribed drugs. The relevant risk depends on the specific medicine, dose, concurrent therapy, and health profile. Serious symptoms, such as marked confusion, fever with muscle rigidity, or severe autonomic instability, demand urgent medical evaluation. NICE CG31; Castle et al., 2021.
Agitation, mania, suicidality, and acute safety
Antidepressant treatment requires explicit attention to emergent suicidality, restlessness or akathisia, agitation, and worsening anxiety, particularly early in treatment and after dose changes. Younger patients require especially careful observation under antidepressant safety warnings and age-specific guidance. Prescribers assess personal and family bipolar history because antidepressants can precipitate mania or hypomania in vulnerable individuals. A clear change in sleep need, energy, risk taking, or mood requires prompt assessment. NICE CG31.
BDD itself can involve substantial suicide risk, independent of decisions about antidepressants. A clinician should ask directly about suicidal thoughts, intent, planning, prior attempts, self-injury, hopelessness, isolation, and access to lethal means; document the formulation; and arrange an appropriate safety plan and level of care. NICE recommends limited medication quantities for adults at high suicide risk and additional contact early in treatment where indicated. Immediate danger warrants emergency assessment and local emergency services rather than waiting for a routine medication appointment. NICE CG31; Rück et al., 2024.
Pregnancy, breastfeeding, age, and medical vulnerability
Pregnancy and breastfeeding decisions require balancing the consequences of untreated psychiatric illness with the potential effects of treatment and discontinuation. The appropriate SSRI depends on clinical history, other medicines, prior response, reproductive circumstances, and current obstetric and psychiatric guidance. A patient considering pregnancy should coordinate a review with the prescriber rather than stopping a beneficial antidepressant abruptly. Older adults and medically complex patients may require additional attention to falls, sodium levels, arrhythmia risk, multiple prescriptions, and drug metabolism. Research specifically examining these groups within BDD treatment remains limited. NICE CG31; Castle et al., 2021.
How Long Does BDD Medication Take, and When Can It Be Stopped?
Early improvement and an adequate trial
Many antidepressant effects emerge over weeks, and change in BDD can require a longer observation window than a patient initially expects. The fluoxetine randomized trial showed clear separation from placebo by approximately the eighth week; specialist guidance considers a sustained, adequately tolerated course important before labeling a medication ineffective. Early clinical follow-up remains necessary despite this slower benefit, because adverse reactions and suicide risk need attention from the outset. Phillips et al., 2002; NICE CG31.
Continuation, maintenance, and relapse
Response is not the same as complete remission. Residual rituals, intrusive thoughts, or avoidance may remain after measurable improvement, and some patients continue improving with maintenance care. In the escitalopram randomized discontinuation study, continuing the medication reduced relapse compared with switching to placebo over six months in participants who had already responded. These data support discussing continuity after response, although treatment duration still needs to be individualized. Phillips et al., 2016.
NICE recommends continuing an effective SSRI in adults for at least 12 months to reduce relapse risk and allow further improvement, and reviewing the need for ongoing treatment after sustained remission with attention to illness history, residual symptoms, stressors, and preferences. For children and young people who respond, NICE recommends medication continuation for at least six months after remission, with specialist monitoring. These are guideline recommendations and cannot replace follow-up tailored to the person and to the available evidence. NICE CG31.
Discontinuation and withdrawal
Abrupt cessation or irregular dosing can cause discontinuation symptoms, and worsening BDD after stopping may represent relapse, withdrawal, or both. Symptoms of antidepressant withdrawal may include dizziness, sleep disturbance, sensory disturbances, nausea, irritability, and anxiety. NICE advises a gradual reduction coordinated with a healthcare professional, adjusted to the drug's half-life, dose, duration, individual responses, and any withdrawal symptoms. Continuing psychological skills and monitoring for renewed appearance rituals helps distinguish and respond to emerging problems. NICE CG31.
What If the First Medication Does Not Help?
First verify the treatment trial
An insufficient response calls for a structured review rather than an automatic succession of drugs. The clinician re-examines the diagnosis and comorbidities, verifies the dose and duration that were actually tolerated, asks about missed doses and interactions, assesses adverse effects, and revisits whether specialized CBT is accessible. Avoidance or appearance-related shame may interfere with attendance and adherence. Clinical depression, significant substance use, bipolarity, psychotic symptoms, and eating pathology may also change the plan. NICE CG31; Castle et al., 2021.
Optimize, switch, or combine evidence-based care
NICE recommends combined CBT with ERP and an SSRI after an inadequate response to an adequate course of either alone in specified circumstances. After inadequate response to combined treatment, or where SSRI monotherapy has failed or CBT could not be engaged, it recommends considering another SSRI or clomipramine. These decisions involve medical review and patient preferences. Where repeated adequate trials fail, the guideline recommends a multidisciplinary specialist BDD/OCD service to reassess symptom patterns, adherence, comorbidities, function, and safety. NICE CG31.
Augmentation with an antipsychotic or experimental agent is a specialist decision resting on limited BDD-specific evidence, side-effect burden, and a careful analysis of treatment resistance. An isolated apparent success in a published case report cannot establish a generalizable prescription algorithm. Patients should be told when evidence is preliminary or extrapolated from another condition. Castle et al., 2021.
Medication for BDD in Children and Adolescents
BDD commonly begins during adolescence, but pediatric medication studies are much fewer than adult studies. NICE recommends developmentally adapted CBT involving families or caregivers as the first-line treatment for children and young people. If a full CBT course has been insufficient, a multidisciplinary review is recommended; medication may be considered or added according to age, functional impairment, and shared specialist assessment. NICE specifies fluoxetine when an SSRI is prescribed for BDD in young people, while highlighting off-label use. NICE CG31; Rück et al., 2024.
SSRIs for pediatric BDD should be prescribed and reviewed by a child and adolescent psychiatrist, with age-appropriate monitoring, family involvement, and close assessment for agitation, hostility, self-harm, and emergent suicidal thoughts. Doses for adults must not be transferred to children. Care arrangements should support school functioning, family relationships, privacy, and developmentally appropriate autonomy. Clinical attention is also needed to avoid treating ordinary pubertal change, culturally specific appearance values, or a transgender or gender-diverse identity as evidence of BDD. NICE CG31.
Medication, Insight, Cosmetic Care, and Related Diagnoses
Poor insight and delusional-intensity appearance beliefs
A patient may believe a perceived defect is unquestionably real even when objective examination does not support it. Within BDD, this is described through the insight specifier. The evidence for serotonin reuptake treatment includes patients with poor insight and delusional intensity; clinicians should therefore assess the overall syndrome and determine whether other psychotic symptoms indicate a separate or coexisting disorder. Prescribing an antipsychotic solely because of strong conviction about an appearance flaw is not the general first-line BDD pathway. Hollander et al., 1999; NICE CG31.
Cosmetic procedures and treatment expectations
Cosmetic surgery, dermatological treatments, or repeated aesthetic procedures are often sought by people with BDD in the hope of removing distress. When BDD is present, changes to appearance frequently fail to resolve the underlying preoccupation or compulsive patterns. Clinicians should communicate with relevant medical specialists and address the psychiatric disorder, informed consent, and safety rather than encouraging repeated attempts to perfect a perceived flaw. A medication response is assessed by psychological symptoms and functioning, not by whether an appearance procedure becomes possible. Castle et al., 2021.
OCD, eating disorders, social anxiety, and muscle dysmorphia
BDD and OCD share intrusive preoccupations and repetitive responses, which partially explains overlaps in psychotherapy and pharmacological practice. Their clinical content and differential diagnoses remain distinct. In eating disorders, appearance and body-shape concerns may be embedded in disturbances of eating, restriction, binge eating, or compensatory behaviors, requiring eating-disorder assessment and specific treatment. In social anxiety disorder, the primary fear concerns negative evaluation more generally; BDD involves a perceived appearance defect with characteristic preoccupation and repetitive behaviors. Muscle dysmorphia, when present, requires assessment of compulsive training, supplement or anabolic-androgenic steroid use, and related medical risks. Rück et al., 2024.
These distinctions affect medication: SSRIs prescribed for BDD are not automatically the correct intervention for an eating disorder, a bipolar episode, or a substance-related problem. Clinical pathways should address each verified diagnosis while maintaining the BDD-specific treatment target. Castle et al., 2021.
Research Methods, Evidence Quality, and Unanswered Questions
Controlled trials and their limits
The strongest pharmacotherapy design randomly assigns participants to an active treatment or comparison condition and measures outcomes with blinded procedures. BDD medication research includes relatively small acute trials of fluoxetine and clomipramine, open-label investigations of other SRIs, and one important randomized continuation experiment with escitalopram. The comparison conditions and outcome definitions differ, and studies have limited power to test subgroup effects by age, sex, race, gender, or coexisting disorders. Clinicians should avoid presenting percentages across unlike studies as direct comparative drug rankings. Phillips, Albertini, and Rasmussen, 2002; Hollander et al., 1999; Phillips et al., 2016.
What remains uncertain
Comparative effectiveness among individual SSRIs, the minimum effective and safest BDD-specific doses, optimal augmentation strategies, the best duration for different relapse-risk groups, outcomes in pregnant or medically complex patients, and medication treatment in adolescents need stronger trials. The effects of combined CBT and medication may depend on timing and therapist expertise. Current neurobiological hypotheses cannot reliably predict which individual will respond to which medication. A 2024 comprehensive disease primer and the international expert consensus identify treatment evidence while emphasizing the limited pharmacotherapy trial base. Rück et al., 2024; Castle et al., 2021.
Social, cultural, and access-related factors also deserve attention. Delayed identification, fear of disclosure, lack of BDD-trained clinicians, insurance or financial barriers, and stigma can shape what treatment patients receive. Clinical research with diverse groups and transparent long-term outcomes is needed to determine how well established trial findings generalize. Treatment planning should respect disability, weight diversity, racial and ethnic contexts, and gender identity, none of which constitutes a BDD diagnosis. Jonathan et al., 2024; Rück et al., 2024.
Practical Questions About BDD Medication
Does medication cure body dysmorphic disorder?
SSRIs can reduce BDD symptoms and improve functioning; some people achieve substantial remission, while others have partial responses or recurrence. The clinical aim is sustained reduction in impairment and appearance-focused rituals with monitoring, support, and appropriate psychological care. Controlled evidence supports benefit, but individual results cannot be guaranteed. Rück et al., 2024.
Is fluoxetine always the best SSRI?
Fluoxetine has a particularly clear direct trial and is the first pharmacological option named by NICE for BDD. That evidence does not prove superiority over every other SSRI, because adequate direct comparison trials are lacking. Prior response, adverse effects, drug interactions, medical conditions, and patient preference help determine an individual prescription. NICE CG31; Castle et al., 2021.
What if I feel worse after starting an SSRI?
New agitation, restlessness, marked anxiety, mood activation, or suicidal thinking requires prompt contact with the treating service; severe symptoms or immediate danger require emergency evaluation. Prescribers review the medication, assess safety, and determine whether the regimen must change. The existence of gradual treatment effects does not justify enduring serious adverse reactions without clinical advice. NICE CG31.
Can an SSRI help BDD with delusional-level conviction?
Yes, clinically meaningful responses have occurred in studies including participants with delusional-level appearance beliefs. A clinician still determines whether a separate psychotic or mood disorder is present. Strong conviction alone is not evidence that antipsychotic monotherapy is the standard BDD treatment. Hollander et al., 1999; NICE CG31.
Is medication enough without therapy?
Some adults with moderate BDD impairment may choose an SSRI as an initial treatment. For severe impairment, NICE recommends combined specialized CBT and an SSRI. Treatment choice depends on severity, available care, side effects, comorbidities, and patient preferences; follow-up measures both the symptoms and the ability to resume meaningful activities. NICE CG31.
Can medication be stopped once symptoms improve?
Stopping immediately after improvement can expose a person to relapse and discontinuation symptoms. NICE recommends an adequate continuation period and a gradual clinician-supervised taper when stopping is appropriate. The randomized escitalopram continuation study found lower relapse during continued treatment than after switching to placebo. Phillips et al., 2016; NICE CG31.
Clinical Synthesis
For BDD, SSRIs have the strongest established medication role, with fluoxetine supported by a direct placebo-controlled trial and prioritized in NICE guidance; clomipramine has controlled evidence but a less favorable safety and monitoring profile. Escitalopram maintenance has randomized relapse-prevention support among prior responders. CBT tailored to BDD is an essential evidence-based pathway, especially when impairment is severe or persistent. Individualized prescribing, adequate duration, safety monitoring, and a measured response to residual symptoms form the clinical basis of responsible treatment. Rück et al., 2024; Castle et al., 2021; NICE CG31.
Related Articles
Body Dysmorphic Disorder: Symptoms, Diagnosis, and Treatment examines clinical recognition, diagnosis, and the overall treatment framework. CBT for Body Dysmorphic Disorder: Evidence and Treatment Approaches details psychotherapy techniques and outcome evidence. Body Dysmorphic Disorder Screening: Tools and Clinical Assessment explains screening limits and diagnostic assessment. Body Dysmorphic Disorder and Cosmetic Procedures: Risks and Clinical Care addresses cosmetic care and risk. OCD vs Body Dysmorphic Disorder distinguishes related clinical syndromes.